CLINICAL_TRIALS
trial_result
· 2018-11-02
Clinical Trial Update: Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3) [Phase 3]
Summary
Phase 3 trial assessing empagliflozin as an adjunct to insulin in adults with type 1 diabetes over 26 weeks has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 1 | Phase 3 | Status: COMPLETED | Results posted: 2018-11-02